Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug

Parabilis Medicines (PBLS) reported Phase 1/2 data for zolucatetide, showing 72.2% response rate in desmoid tumors. The drug demonstrated favorable safety and tolerability. PBLS plans a Phase 3 trial in 2027, with results expected in 2029. The stock is down 9.21% at $24.44.

Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.

Parabilis Medicines' [PBLS] Zolucatetide showed 72.2% ORR at week 32, 100% disease control at 450 mg or higher, with no progressions. FDA-aligned plans aim for PEDESTAL trial initiation in H1 2027 and top-line data in 2029, according to the company's investor update.

Parabilis Medicines [PBLS] reported updated Phase 1/2 data for zolucatetide, showing a 72.2% 32-week ORR at doses ≥450 mg and 100% disease control. The FDA supports a Phase 3 trial with 148 patients, planned for 1H 2027, with topline data expected in 2029.

Parabilis Medicines (PBLS) reported phase 1/2 trial results for zolucatetide, showing a 72.2% response rate in 18 patients and 100% disease control in 46 patients. The company plans to start a phase 3 trial in 2027, with FDA alignment on study design and endpoints. Zolucatetide has Fast Track and Orphan Drug Designations for desmoid tumors.

Parabilis Medicines (PBLS) reported 72.2% ORR and 100% DCR in Phase 1/2 zolucatetide data for desmoid tumors. FDA aligned on Phase 3 trial design, starting H1 2027, with topline results expected in 2029. Company to host investor webcast on October 24, 2026.